Abstract
HNC is the 11th most frequent carcinoma with a world-wide yearly incidence exceeding over half a million cases [1], a 10:1 male gender predilection and country specific variability [2]. The principal risk factors are tobacco and alcohol use and, in a growing population without these exposures, HPV infection.While much progress has been made in understanding the molecular basis of cancer, the 5-year mortality of head and neck cancer has remained approximately 50%. To this date we have not been able to translate as much of our basic science knowledge into significant disease altering therapeutic strategies in terms of local, loco-regional, functional and overall survival. Challenges remain in all aspects of head and neck cancer management: prevention, diagnosis, surgical and non-surgical treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 90-96 |
| Number of pages | 7 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 84 |
| Issue number | SUPPL. 1 |
| DOIs | |
| Publication status | Published - Dec 1 2012 |
Fingerprint
Keywords
- Challenges
- Diagnosis
- Head neck oncology
- Medical oncology
- Prevention
- Radiation oncology
- Surgery
ASJC Scopus subject areas
- Oncology
- Hematology
- Geriatrics and Gerontology
Cite this
Future challenges in head and neck cancer : From the bench to the bedside? / Calabrese, Luca; Ostuni, Angelo; Ansarin, Mohssen; Giugliano, Gioacchino; Maffini, Fausto; Alterio, Daniela; Rocca, Maria Cossu; Petralia, Giuseppe; Bruschini, Roberto; Chiesa, Fausto.
In: Critical Reviews in Oncology/Hematology, Vol. 84, No. SUPPL. 1, 01.12.2012, p. 90-96.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Future challenges in head and neck cancer
T2 - From the bench to the bedside?
AU - Calabrese, Luca
AU - Ostuni, Angelo
AU - Ansarin, Mohssen
AU - Giugliano, Gioacchino
AU - Maffini, Fausto
AU - Alterio, Daniela
AU - Rocca, Maria Cossu
AU - Petralia, Giuseppe
AU - Bruschini, Roberto
AU - Chiesa, Fausto
PY - 2012/12/1
Y1 - 2012/12/1
N2 - HNC is the 11th most frequent carcinoma with a world-wide yearly incidence exceeding over half a million cases [1], a 10:1 male gender predilection and country specific variability [2]. The principal risk factors are tobacco and alcohol use and, in a growing population without these exposures, HPV infection.While much progress has been made in understanding the molecular basis of cancer, the 5-year mortality of head and neck cancer has remained approximately 50%. To this date we have not been able to translate as much of our basic science knowledge into significant disease altering therapeutic strategies in terms of local, loco-regional, functional and overall survival. Challenges remain in all aspects of head and neck cancer management: prevention, diagnosis, surgical and non-surgical treatment.
AB - HNC is the 11th most frequent carcinoma with a world-wide yearly incidence exceeding over half a million cases [1], a 10:1 male gender predilection and country specific variability [2]. The principal risk factors are tobacco and alcohol use and, in a growing population without these exposures, HPV infection.While much progress has been made in understanding the molecular basis of cancer, the 5-year mortality of head and neck cancer has remained approximately 50%. To this date we have not been able to translate as much of our basic science knowledge into significant disease altering therapeutic strategies in terms of local, loco-regional, functional and overall survival. Challenges remain in all aspects of head and neck cancer management: prevention, diagnosis, surgical and non-surgical treatment.
KW - Challenges
KW - Diagnosis
KW - Head neck oncology
KW - Medical oncology
KW - Prevention
KW - Radiation oncology
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84871684424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871684424&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2010.11.001
DO - 10.1016/j.critrevonc.2010.11.001
M3 - Article
VL - 84
SP - 90
EP - 96
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - SUPPL. 1
ER -